Yeji
CRLconf 0.85

balstilimab — CRL

$AGEN · AGENUS INC · second-line cervical cancer
Event date
Date TBD
Sponsor runway
3 mo
$35.0M liquid

Evidence

Company voluntarily withdraws BLA at FDA's recommendation following full approval of pembrolizumab, which came four months earlier than FDA goal date
Source: Press release · 2021-10-22View press release ↗

Comparable historical crls· last 5 years · same event type

No comparable historical outcomes in our database yet — backfill of past readouts arrives next ingestion cycle.

Recent insider activity· ±90 days

8 insiders · 0 buys · 0 sells
Grant
2026-05-15
ARMEN GARO H
See Remarks
4,540 @ $3.58$16K
Grant
2026-05-01
ARMEN GARO H
See Remarks
4,233 @ $3.84$16K
Grant
2026-04-24
O'Day Steven J
Chief Medical Officer
95,333 @
Grant
2026-04-24
Buell Jennifer
See Remarks
5,000 @
Grant
2026-04-24
Charette Austin
Principal Accounting Officer
5,000 @
Grant
2026-04-24
Charette Austin
Principal Accounting Officer
17,619 @
Grant
2026-04-24
O'Day Steven J
Chief Medical Officer
70,000 @
Grant
2026-04-24
HARRISON THOMAS L
Director
122,500 @
Grant
2026-04-24
ARMEN GARO H
See Remarks
1,000,000 @
Grant
2026-04-24
ARMEN GARO H
See Remarks
27,750 @
Grant
2026-04-24
ARMEN GARO H
See Remarks
137,550 @
Grant
2026-04-24
Corvese Brian
Director
210,000 @
Grant
2026-04-24
Wright Timothy
Director
105,000 @
Grant
2026-04-24
Hirsch Susan B
Director
105,000 @
Grant
2026-04-24
Buell Jennifer
See Remarks
300,000 @
Grant
2026-04-17
ARMEN GARO H
See Remarks
3,403 @ $4.79$16K
Grant
2026-04-03
ARMEN GARO H
See Remarks
4,629 @ $3.33$15K
Grant
2026-04-01
HARRISON THOMAS L
Director
9,228 @ $3.32$31K
Grant
2026-04-01
Wright Timothy
Director
2,448.256 @
Grant
2026-03-20
ARMEN GARO H
See Remarks
3,983 @ $3.71$15K